欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (6): 668-672.

• 临床药理学 • 上一篇    下一篇

石杉碱甲缓释片多剂量给药健康人体药代动力学研究

魏振满1, 丁晋彪1, 胡琳1, 陈红鸽1, 吴荣荣1, 刘万卉2, 沙春洁2   

  1. 1解放军302医院临床药理室,北京 100039;
    2烟台大学药学院,烟台 264005,山东
  • 收稿日期:2010-03-03 修回日期:2010-03-31 出版日期:2010-06-26 发布日期:2020-09-16
  • 基金资助:
    国家科技部十一五重大新药创制课题(2008ZX09312-011)

Pharmacokinetics of Huperzine A substain-release tablets after multiple doses in healthy volunteers

WEI Zhen-man1, DING Jin-biao1, HU Lin1, CHEN Hong-ge1, WU Rong-rong1, LIU Wan-hui2, SHA Chun-jie2   

  1. 1 Department of Clinical Pharmacology, 302 Hospital, Beijing 100039, China;
    2 Pharmacy College of Yantai University, Yantai 264005, Shandong, China
  • Received:2010-03-03 Revised:2010-03-31 Online:2010-06-26 Published:2020-09-16

摘要: 目的: 评价石杉碱甲缓释片多剂量给药在健康人体药代动力学规律。方法: 采用双周期自身随机交叉试验设计。24名健康志愿者多次口服试验药石杉碱甲缓释片或参比制剂,采用LC-MS/MS测定血浆中药物浓度,药动学参数采用DAS软件处理获得。结果: 试验制剂石杉碱甲缓释片组与参比制剂石杉碱甲普通片组的Css min分别为(0.54±0.21)和(0.79±0.20)ng/mL,Css max分别为(1.65±0.45)和(1.83±0.37)ng/mL,Css分别为(1.05±0.28)和(1.22±0.28)ng/mL,tmax分别为(3.5±1.9)和(1.1±0.4)h,AUC0-t(ss)分别为(31±8)和(35±9)ng·mL-1·h,AUC0-∞(ss)分别为(37±10)和(41±11)ng·mL-1·h,AUCss分别为(25±7)和(15±3) ng·mL-1·h;相对于参比制剂,受试制剂的生物利用度Fss 0-tn为(88±12)%。受试制剂和参比制剂的AUC0-t和AUC0-∞经对数转换后进行方差分析,两制剂间变化相近(P>0.05),受试制剂tmax明显比参比制剂有所延长(P<0.05),明显具有缓释的特征。结论: 试验制剂石杉碱甲缓释片具有明显的缓释特征。

关键词: 石杉碱甲, 药代动力学, 液相色谱/串联质谱

Abstract: AIM: To evaluate the pharmacokinetics of Huperzine A sustained-release tablets after multiple doses in Chinese healthy volunteers. METHODS: In a randomized crossover trial, 24 healthy subjects received multiple oral doses of either Huperzine A sustained-release tablets or a common Huperzine A tablet for 7 days. The plasma concentrations were determined by LC/MS/MS. Pharmacokinetic parameters were obtained using DAS program. RESULTS: The major pharmacokinetic parameters of test and reference Huperzine A tables were as follows: Css min were (0.54±0.21) and (0.79±0.20)ng/mL,Css max were (1.65±0.45)and (1.83±0.37)ng/mL,Css were (1.05±0.28) and (1.22±0.28)ng/mL,tmax were (3.5±1.9) and (1.1±0.4) h,AUC0-t(ss) were (31±8) and (35±9)ng·mL-1·h,AUC0-∞(ss) were (37±10)and (41±11)ng·mL-1·h,AUCss were (25±7)and (15±3)ng·mL-1·h,respectively. The relative bioavailability of test tablet as estimated by AUC0-t(ss) was (88±12) %. There was significant difference in tmax between two tablets. CONCLUSION: The results show that the Huperzine A substain-release tablets clearly have the characteristic of slow releasing properties.

Key words: Huperzine A, Pharmacokinetics, LC/MS/MS

中图分类号: